<DOC>
	<DOCNO>NCT02741362</DOCNO>
	<brief_summary>This Phase I-II open- label single-dose study subject significant refractory Rheumatoid Arthritis ( RA ) , relapse Systemic Lupus Erythematosus ( SLE ) Sharp 's Syndrome ( SS ) . This study enroll minimum 20 subject RA , 20 subject SLE 20 patient SS . 6 week data serum Tumor Necrosis Factor- alpha ( TNFa ) , Interleukin- 6 ( IL-6 ) , C- Reactive Protein ( CRP ) , Erythrocyte Sedimentation Rate ( ESR ) , Cluster Differentiation ( CD ) 4 +CD25 + Forkhead box P3 ( Foxp3 ) + regulatory T cell , Disease Activity Score 28 joint ( DAS-28 ) score pain score collect patient enrol study RA group ( Baseline 6 week ) . For SLE group , Transforming Growth Factor- beta ( TGF-β ) , TNFa , IL-6 , Interleukin- 17 ( IL-17 ) , CD3+CD8-IL17A+ T helper-17 ( Th17 ) cell , CD4+CD25+Foxp3+ regulatory T cell Systemic Lupus Erythematosus Quality Life Questionnaire ( SLEQoL ) score collected subject group . SS group undergo assessment RA SLE . Prior stem cell treatment , patient assess 6 week previously mention marker . Then , patient receive infusion stromal vascular fraction cell contain adult adipose derived stem cell 'aADSC ' ( single intravenous dose ) . The disease- modifying anti-rheumatic drug ( DMARDs ) standard SLE treatment interrupted exception systemic steroid ( exclude minimal maintenance dose one steroid ) duration study . Follow visit take place 6 week , 3 Months 6 Months cell infusion . Safety monitor ongoing basis , interim safety review conduct Investigator ( ) Sponsor first 10 patient enrol treated group .</brief_summary>
	<brief_title>Safety Efficacy Adipose Derived Stem Cells Refractory Rheumatoid Arthritis , Systemic Lupus Erythematosus Sharp 's Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Mixed Connective Tissue Disease</mesh_term>
	<criteria>1 . Males Females ≥18 year 2 . Cognitive competitiveness . 3 . Diagnosis refractory RA ( patient 's poor response 3 month DMARDs determine documented rheumatologist ) , diagnosis relapse SLE ( 2 episode year optimal medical SLE therapy ) diagnosis Sharp syndrome ( AlarconSegovia 's criterion : patient U1 Ribonucleic protein ( RNP ) ≥ 1:1600 , three follow : Swollen hand , Synovitis , Myositis , Raynauld 's phenomenon , Acrosclerosis ) 4 . Life expectancy great 8 month 5 . Ability understand provide sign informed consent , designated legal guardian spouse legally able willing make decision subject 's behalf 6 . Reasonable expectation patient receive standard posttreatment care attend schedule safety followup visit 7 . No change active pulmonary medication heart failure two week prior enrollment . 8 . Written inform consent 1 . Currently systemic steroid ( chronic steroid therapy stop , patient qualify he/she minimum maintenance dose per SLE , RA SS guideline one systemic steroid constitute bioequivalent normal endogenous level hormone ) . 2 . Dementia . 3 . Presence immune deficiency . 4 . Currently NSAIDs , TNFa inhibitor , Calcium channel blocker P2Y12 inhibitor 5 . Complicated type 2 diabetes mellitus ( presence diabetic foot , advance kidney disease retinopathy ) . 6 . History cancer within past 5 year . 7 . Presence clinicallysignificant medical condition , psychiatric condition , laboratory abnormality , judgment Investigator Sponsor participation study would pose safety risk subject 8 . Participation another study investigational drug device within 3 week prior treatment 9 . History within past year drug alcohol abuse . 10 . Females know pregnant , lactate positive pregnancy test ( test screening ) planning become pregnant study . 11 . Inability comply condition protocol . 12 . Porphyria . 13 . Allergy sodium citrate `` caine '' type local anesthetic . 14 . Patient schedule hospice care .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Type III hypersensitivity autoimmune disease</keyword>
</DOC>